Capricor Therapeutics (NASDAQ:CAPR) Releases Earnings Results, Misses Estimates By $0.04 EPS

kopsource · Aug 12, 2022 05:21

Capricor Therapeutics (NASDAQ:CAPR – Get Rating) issued its earnings results on Wednesday. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04), Fidelity Earnings reports. During the same period last year, the firm earned ($0.21) EPS.

Capricor Therapeutics Stock Performance

CAPR traded up $0.76 during trading on Thursday, hitting $5.28. The stock had a trading volume of 569,778 shares, compared to its average volume of 229,072. Capricor Therapeutics has a twelve month low of $2.56 and a twelve month high of $5.85. The stock has a 50 day simple moving average of $4.23 and a two-hundred day simple moving average of $3.96. The company has a market capitalization of $128.43 million, a PE ratio of -5.50 and a beta of 5.00.

Get Capricor Therapeutics alerts:

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Capricor Therapeutics to a "sell" rating in a research report on Monday, May 23rd.

Insider Transactions at Capricor Therapeutics

In related news, Director David B. Musket sold 28,215 shares of the firm's stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total transaction of $106,370.55. Following the completion of the transaction, the director now owns 12,747 shares of the company's stock, valued at $48,056.19. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director David B. Musket sold 17,775 shares of the business's stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $4.44, for a total transaction of $78,921.00. Following the transaction, the director now directly owns 40,962 shares in the company, valued at $181,871.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David B. Musket sold 28,215 shares of the business's stock in a transaction dated Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total transaction of $106,370.55. Following the completion of the transaction, the director now owns 12,747 shares in the company, valued at $48,056.19. The disclosure for this sale can be found here. Insiders own 9.00% of the company's stock.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Capricor Therapeutics by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company's stock valued at $3,502,000 after acquiring an additional 54,260 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Capricor Therapeutics by 54.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 148,768 shares of the biotechnology company's stock valued at $510,000 after acquiring an additional 52,611 shares during the period. State Street Corp raised its stake in shares of Capricor Therapeutics by 10.4% in the 1st quarter. State Street Corp now owns 79,224 shares of the biotechnology company's stock valued at $272,000 after acquiring an additional 7,476 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Capricor Therapeutics by 38.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 42,238 shares of the biotechnology company's stock valued at $145,000 after acquiring an additional 11,821 shares during the period. Finally, UBS Group AG raised its stake in shares of Capricor Therapeutics by 326.0% in the 2nd quarter. UBS Group AG now owns 29,352 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 22,462 shares during the period. 9.49% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

(Get Rating)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured Articles

Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Find and Profitably Trade Stocks at 52-Week Lows
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
3 Stable Growth Stocks for Bumpy Times
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.